Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Oncothyreon Inc (ONTY)

Oncothyreon Inc (ONTY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Oncothyreon Inc 2601 FOURTH AVENUE SUITE 500 SEATTLE WA 98121

www.oncothyreon.com P: 206-801-2100

Description:

Oncothyreon Inc., formerly Biomira Inc. is a clinical-stage biopharmaceutical company focused primarily on the development and commercialization of therapeutic products for the treatment of cancer. The company is currently developing multiple therapeutic candidates designed to target cancer in specific and effective ways. Headquartered in Seattle, Washington, the primary goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. The Company's lead product candidate is Stimuvax, which is a cancer vaccine in Phase III development for non-small cell lung cancer. Oncothyreon has an exclusive, worldwide collaboration agreement with Merck KGaA of Darmstadt, Germany, for the development and commercialization of Stimuvax. Its pipeline of clinical and preclinical-stage small molecule product candidates includes PX-12, PX-478 and PX-866, from ProlX Pharmaceuticals Corporation.

Key Statistics

Overview:

Market Capitalization, $K 115,850
Shares Outstanding, K 94,960
Annual Sales, $ 0 K
Annual Net Income, $ -32,580 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -12,890 K
60-Month Beta 1.88
% of Insider Shareholders 23.10%
% of Institutional Shareholders 59.72%

Growth:

1-Year Return -70.34%
3-Year Return -34.59%
5-Year Return -85.06%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth -48.48%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.14 on 05/09/16
Latest Earnings Date N/A
Earnings Per Share ttm -0.43
EPS Growth vs. Prev Qtr -40.00%
EPS Growth vs. Prev Year -133.33%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payable Date 12/31/69
Dividend Payout Ratio 0.00%
Most Recent Split 1-6 on 12/11/07

ONTY Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -46.42%
Return-on-Assets % -40.47%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 1.37
Book Value/Share 0.78
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar